KeifeRx, LLC, is an emerging clinical-stage biopharmaceutical company developing a pipeline of optimized, lower dose, orally delivered tyrosine kinase inhibitors (TKIs) for the treatment of multiple, high-need neurodegenerative diseases. KeifeRx’s optimized TKIs are designed to penetrate the brain, induce autophagy, and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and Lewy Body Dementia, through the bulk disposal of disease-causing toxic proteins. This approach offers the potential to significantly improve upon current neurodegenerative disease treatments, which are only palliative and offer minimal benefits due to their inability to adequately eliminate the toxic proteins that are the root of these deadly diseases.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Virginia
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Lead Product in Development:
Nilotinib BE
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
